SBS highlights investor chance to lead securities fraud class action against Capricor Therapeutics, underscoring rising litigation risk in the biotech sector
Executive summary: SBS reminded investors of a class action lawsuit against Capricor Therapeutics for alleged securities fraud and invited them to seek lead plaintiff status. The opportunity to become lead plaintiff can shape the litigation’s direction, potential settlement terms, and the company’s legal costs, making it a material event for shareholders.
Who is involved: Schall, Brown & Schwartz LLP (SBS), Capricor Therapeutics (NASDAQ: CAPR), and affected investors.
Likely next: Investors may contact SBS before the September 28, 2026 lead plaintiff deadline; the court will then consider motions for lead plaintiff appointment, after which the case proceeds through discovery and possible settlement or trial.
Schall, Brown & Schwartz LLP (SBS) issued a press release reminding Capricor Therapeutics investors of their opportunity to serve as lead plaintiff in a securities fraud lawsuit alleging violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934. The notice coincides with similar SBS alerts for other companies, indicating a coordinated effort to recruit lead plaintiffs in multiple contemporaneous class actions. While the release does not allege new wrongdoing, it signals ongoing litigation exposure that could affect Capricor’s share price and require increased legal and compliance spending.
Timeline
- — Peabody Energy Corporation Investor Alert: Contact SBS by August 24, 2026 for Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
- — RXT Investors Have Opportunity to Lead Rackspace Technology, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
- — Planet Fitness, Inc. Investor Alert: Contact SBS by September 14, 2026 for Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- September 28, 2026 deadline to seek lead plaintiff role in the Capricor securities class action (per Aug 14 notice).
- August 16, 2026 Kessler Topaz Meltzer & Check LLP urges CAPR investors with losses to contact the firm regarding the lawsuit.
- SBS may file a motion to be appointed lead plaintiff before the September 28 deadline.
Sectors affected
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Potential SEC enforcement under §§10(b) and 20(a) of the Securities Exchange Act of 1934.
- Increased scrutiny from FINRA and possible industry-wide impact on biotech litigation trends.
Historical parallels
- August 13, 2026 SBS reminder of lead plaintiff opportunity for Capricor Therapeutics (PR Newswire).
- August 10, 2026 earlier SBS reminder for Capricor Therapeutics investors (PR Newswire).
Key entities
Sources
Open the full interactive case file on Beyond →